Stay updated on Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.

Latest updates to the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the pembrolizumab-and-tamoxifen breast cancer study, including its study details, eligibility criteria, contacts, and outcomes.SummaryDifference50%

- Check18 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH’s transition to using “Super Intelligence” instead of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check39 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.0 to v3.7.1, while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check46 days agoChange DetectedThe study record page shows a 403 Forbidden message with a link back to Home, and the trial details are unavailable.SummaryDifference0.6%

Stay in the know with updates to Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.